The efficacy of rituximab in the treatment of refractory chronic inflammatory demyelinating polyneuropathy in children: A report of three cases from Northern Vietnam
Nội dung chính của bài viết
Tóm tắt
Rituximab has been reported to be effective in patients with refractory CIDP, especially those with IgG4 autoantibodies against nodal and paranodal proteins. This study reports the clinical characteristics of three cases diagnosed with refractory CIDP successfully treated with rituximab, although testing for IgG4 antibodies is currently not available in Vietnam. Patients were evaluated using the MRC (Medical Research Council Scale for Muscle Strength) and INCAT (Inflammatory Neuropathy Cause and Treatment) scores before and after rituximab treatment. The duration of the disease before rituximab treatment ranged from 6 to 10 months, with total MRC scores of 16 - 26 points, INCAT scores of 8 - 9 points, and the first response noted after 1 - 4 months. Patients recovered well after a follow-up period of 8 to 12 months without adverse effects, with MRC and INCAT scores improving to 48 - 58 points and 1 - 2 points, respectively. Rituximab may be effective in treating refractory CIDP patients.
Chi tiết bài viết
Từ khóa
CIDP, treatment resistance, children, rituximab
Tài liệu tham khảo
2. Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision. J Peripher Nerv Syst. 2021;26(3):242-268. doi:10.1111/jns.124550.
3. Cocito D, Grimaldi S, Paolasso I, et al. Immunosuppressive treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy. A nationwide retrospective analysis. Eur J Neurol. 2011;18(12):1417-1421. doi:10.1111/j.1468-1331.2011.03495.x.
4. Qiu JL, Huang L, Shao MY, et al. Efficacy and safety of azithromycin combined with glucocorticoid on refractory Mycoplasma pneumoniae pneumonia in children: A PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore). 2020;99(22). doi:10.1097/MD.0000000000020121.
5. Shimizu S, Iijima M, Fukami Y, et al. Efficacy and safety of rituximab in refractory CIDP with or without IgG4 autoantibodies (RECIPE): protocol for a double-blind, randomized, placebo-controlled clinical trial. JMIR Res Protoc. 2020;9(4).
6. Hughes RA, Newsom-Davis JM, Perkin GD, et al. Controlled trial prednisolone in acute polyneuropathy. Lancet Lond Engl. 1978;2(8093):750-753. doi:10.1016/s0140-6736(78)92644-2.
7. Ruts L, Koningsveld R van, Doorn PA van. Distinguishing acute-onset CIDP from Guillain–Barré syndrome with treatment related fluctuations. Neurology. 2005;65(1):138-140. doi:10.1212/01.wnl.0000167549.09664.b8.
8. Querol L, Rojas-García R, Diaz-Manera J, et al. Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins. Neurol Neuroimmunol Neuroinflammation. 2015;2(5). doi:10.1212/NXI.0000000000000149.
9. Benedetti L, Briani C, Franciotta D, et al. Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a report of 13 cases and review of the literature. J Neurol Neurosurg Psychiatry. 2011;82(3):306-308.
10. Fatehi F, et al. Retrospective analysis of response to rituximab in chronic inflammatory demyelinating polyneuropathy refractory to first-line therapy. J Peripher Nerv Syst. 2021;26(4):469-474. doi: 10.1111/jns.12461.
11. Delmont E, Brodovitch A, Kouton L, et al. Antibodies against the node of Ranvier: a real-life evaluation of incidence, clinical features and response to treatment based on a prospective analysis of 1500 sera. J Neurol. 2020;267:3664-3672.